U.S. Markets close in 3 hrs 9 mins

Wired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting

Stock Monitor: Titan Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CNAT as the Company's latest news hit the wire. On April 09, 2018, the Company announced that it will present research results showing reductions in bacteria-driven inflammation and related liver injury with the Company's pan-caspase inhibitor, IDN-7314, in a mouse model of primary sclerosing cholangitis (PSC) at the International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris, France, April 11-15, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), which also belongs to the Healthcare sector as the Company Conatus Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=TTNP

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Conatus Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CNAT

Gut-Liver Connection Plays a Critical Role in PSC Onset and Progression

The researchers noted that PSC is strongly associated with inflammatory bowel disease, and that the gut-liver connection plays a critical role in PSC onset and progression. They investigated gut-liver interactions and inflammasome activation in the Mdr2−/− mouse model resembling PSC. Their results showed that inflammation in the Mdr2−/− mouse model showed characteristic increases in apoptotic cell death, progressive bile duct proliferation and periportal fibrosis development.

IDN-7314 Demonstrated Beneficial Effects on Liver Injury, Periportal Inflammation and Serum Bile Acid Profile

IDN-7314 was administered as a treatment to block caspase activation, resulting in reduced inflammasome activation and demonstrated beneficial effects on liver injury, periportal inflammation, serum bile acid profile as well as imbalance in the intestinal bacteria. The researchers confirmed the importance of the gut-liver connection in the Mdr2−/− mouse model of PSC and concluded that blockage of bile ducts triggers an intestinal bacteria imbalance and migration of bacteria and related toxins to the portal vein of the liver, followed by increased inflammation and liver injury. They further concluded that this cascade of events can be blocked by pan-caspase inhibition.

EMA Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC

In October 2017, the European Medicines Agency (EMA) granted orphan designation to IDN-7314 for the treatment of PSC. The EMA's orphan designation program is intended to encourage the development of medicines that may provide benefit to patients suffering from rare life-threatening or chronically debilitating conditions. IDN-7314 was granted Orphan Drug Designation for the treatment of PSC by the US Food and Drug Administration (FDA) in June 2017.

About Primary Sclerosing Cholangitis (PSC)

PSC is a long-term progressive disease of the liver and gallbladder characterized by inflammation and scarring of the bile ducts which normally allow bile to drain from the gallbladder. Affected individuals may have no symptoms or may experience signs and symptoms of liver disease such as yellow discoloration of the skin and eyes, itching, and abdominal pain. The bile duct scarring which occurs in PSC narrows the ducts of the biliary tree and impedes the flow of bile to the intestines. Eventually, this can lead to cirrhosis of the liver and liver failure.

About IDN-7314

IDN-7314 is an orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), which has demonstrated reduction of relevant biomarkers in two preclinical models of PSC. The Mdr2-/- mouse model is considered the current benchmark non-clinical model of PSC. Conatus is evaluating the potential of IDN-7314 as a treatment for PSC.

About Conatus Pharmaceuticals Inc.

Founded in 2005 and headquartered in San Diego, California, Conatus Pharma is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. The Company's lead compound, emricasan, is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases, which are enzymes that mediate inflammation and apoptosis.

Stock Performance Snapshot

April 10, 2018 - At Tuesday's closing bell, Conatus Pharma's stock marginally advanced 0.51%, ending the trading session at $3.97.

Volume traded for the day: 731.88 thousand shares, which was above the 3-month average volume of 720.63 thousand shares.

After yesterday's close, Conatus Pharma's market cap was at $121.96 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.8% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors